• Sonoma Pharmaceuticals Inc SNOA.OQ reported a quarterly adjusted loss of 76 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.40. The lone analyst forecast for the quarter was for a loss of 51 cents per share.

• Revenue rose 18.4% to $4.02 million from a year ago; analysts expected $4.05 million.

• Sonoma Pharmaceuticals Inc's reported EPS for the quarter was a loss of 76 cents​.

• The company reported a quarterly loss of $1.24 million.

• Sonoma Pharmaceuticals Inc shares had risen by 6.2% this quarter and gained 12.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 16.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Sonoma Pharmaceuticals Inc is $14.80, about 79% above its last closing price of $3.11

This summary was machine generated from LSEG data August 8 at 03:20 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)